Search

Your search keyword '"Khachatryan N"' showing total 163 results
Start Over Author "Khachatryan N"
163 results on '"Khachatryan N"'

4. Interval total colorings of graphs

Author

Petrosyan, P. A., Torosyan, A. Yu., and Khachatryan, N. A.

Subjects
Computer Science - Discrete Mathematics
Abstract

A total coloring of a graph $G$ is a coloring of its vertices and edges such that no adjacent vertices, edges, and no incident vertices and edges obtain the same color. An \emph{interval total $t$-coloring} of a graph $G$ is a total coloring of $G$ with colors $1,2,\...,t$ such that at least one vertex or edge of $G$ is colored by $i$, $i=1,2,\...,t$, and the edges incident to each vertex $v$ together with $v$ are colored by $d_{G}(v)+1$ consecutive colors, where $d_{G}(v)$ is the degree of the vertex $v$ in $G$. In this paper we investigate some properties of interval total colorings. We also determine exact values of the least and the greatest possible number of colors in such colorings for some classes of graphs., Comment: 23 pages, 1 figure

Published
2010

5. ON THE HAZARDS OF VIOLATION OF THE ENVIRONMENTAL STATE ENVIRONMENTAL IN OPEN AND UNDERGROUND MINING MINERAL RESOURCES OF ARMENIA

Author

Ghukasyan, A., Matevosyan, L., Khachatryan, N., and Galstyan, M.

Subjects
ecological state, risk assessment, environment, minerals, tailings
Abstract

The article describes the results of the research on the evaluation of the state of ecological impact of the environment caused by the exploitation of minerals in the republic. Studies have revealed that both mining and agricultural organizations, in order to provide ecologically safe food from the land, must perfectly implement the requirements of the laws adopted by the RA government on the preservation of land and water resources and the exploitation of the mining industry.

Published
2023
Full Text
View/download PDF

6. DESCRIPTION AND ECONOMIC INDICATORS OF WINTER BARLEY VARIETY SIS

Author

Mkrtchyan, A., Gukasyan, A., Osipova, R., and Khachatryan, N.

Subjects
winter barley, selection, variety, productivity, early maturity, economic efficiency
Abstract

The article describes in detail a new variety of winter barley Sis, obtained on the basis of the variety Mush by the method of individual selection. The indicators of germination energy and seed germination, growth dynamics of 10-day-old seedlings, coleoptile and roots in laboratory conditions are given. The indicators of productivity and structural elements of the crop of the variety, as well as the economic efficiency of its cultivation, are calculated. The variety is early maturing. The yield of the Sis variety is higher than that of the control variety Mush by 12.8-15.5%, and the level of cultivation profitability by 20%. The variety is recommended to be cultivated in the Ararat valley, the foothill zone of the Ararat basin, Vayots Dzor and Zangezur zones.

Published
2023
Full Text
View/download PDF

8. Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Author

Zeng, C., primary, Mitnick, C. D., additional, Hewison, C., additional, Bastard, M., additional, Khan, P., additional, Seung, K. J., additional, Rich, M. L., additional, Atwood, S., additional, Melikyan, N., additional, Morchiladze, N., additional, Khachatryan, N., additional, Khmyz, M., additional, Restrepo, C. G., additional, Salahuddin, N., additional, Kazmi, E., additional, Dahri, A. A., additional, Ahmed, S., additional, Varaine, F., additional, Vilbrun, S. C., additional, Oyewusi, L., additional, Gelin, A., additional, Tintaya, K., additional, Yeraliyeva, L. T., additional, Hamid, S., additional, Khan, U., additional, Huerga, H., additional, and Franke, M. F., additional

Published
2023
Full Text
View/download PDF

10. Integrating hepatitis C treatment into multidrug-resistant TB care

Author

Kirakosyan, O., Melikyan, N., Falcao, J., Khachatryan, N., Atshemyan, H., Oganezova, I., Aznauryan, A., Yeghiazaryan, L., Sargsyants, N., Hayrapetyan, A., Balkan, S., Hewison, C., and Huerga, H.

Subjects
Original Articles
Abstract

Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We describe the implementation aspects of a new integrated model of care in Armenia and the perceptions of the healthcare staff and patients.We used qualitative methods, including a desktop review and semi-structured individual interviews with healthcare staff and with patients receiving HCV and MDR/RR-TB treatment.The new integrated model resulted in simplified management of HCV and MDR/RR-TB at public TB facilities. Training on HCV was provided for TB clinic staff. All MDR/RR-TB patients were systematically offered HCV testing and those diagnosed with HCV, offered treatment with DAAs. Treatment monitoring was performed by TB staff in coordination with a hepatologist. The staff interviewed had a positive opinion of the new model. They suggested that additional training should be provided. Most patients were fully satisfied with the care received. Some were concerned about the increased pill burden.Integrating HCV treatment into MDR/ RR-TB care was feasible and appreciated by patients and staff. This new model facilitated HCV diagnosis and treatment among people with MDR/RR-TB. Our results encourage piloting this model in other settings.Les antiviraux à action directe (DAA) sont peu prescrits aux patients atteints d’hépatite C (HCV) chronique et de TB multirésistante ou résistante à la rifampicine (MDR/RR-TB). Nous décrivons la mise en place d’un nouveau modèle de soins intégrés en Arménie, ainsi que l’opinion du personnel soignant et des patients.Nous avons utilisé des méthodes qualitatives, comprenant un examen électronique de la documentation et des entretiens individuels semi-structurés avec le personnel soignant et les patients sous traitement pour HCV et MDR/RR-TB.Le nouveau modèle intégré a permis de simplifier la prise en charge du HCV et de la MDR/RR-TB dans les centres de soins publics de la TB. Une formation sur le HCV a été dispensée au personnel des centres antituberculeux. Tous les patients atteints de MDR/RR-TB se sont vu systématiquement proposer un test de dépistage du HCV, et un traitement par DAA a été proposé à ceux dont le résultat était positif. Le suivi du traitement a été réalisé par le personnel des centres antituberculeux, conjointement à un hépatologue. Les membres du personnel interrogés avaient une opinion positive du nouveau modèle et suggéraient de dispenser d’autres formations. La plupart des patients étaient pleinement satisfaits des soins reçus, mais certains étaient inquiets au vu du nombre accru de comprimés à prendre.L’intégration du traitement du HCV aux soins de la MDR/RR-TB s’est avérée possible et a été appréciée par les patients et le personnel soignant. Ce nouveau modèle a facilité le diagnostic et le traitement du HCV chez les patients atteints de MDR/RR-TB. Ce modèle devrait être testé dans d’autres contextes.

Published
2022

11. Integrating hepatitis C treatment into multidrug-resistant TB care

Author

Kirakosyan, O., primary, Melikyan, N., additional, Falcao, J., additional, Khachatryan, N., additional, Atshemyan, H., additional, Oganezova, I., additional, Aznauryan, A., additional, Yeghiazaryan, L., additional, Sargsyants, N., additional, Hayrapetyan, A., additional, Balkan, S., additional, Hewison, C., additional, and Huerga, H., additional

Published
2022
Full Text
View/download PDF

14. Author correction: Perceptions of the appropriate response to norm violation in 57 societies

Author

Eriksson, K., Strimling, P., Gelfand, M., Wu, J., Abernathy, J., Akotia, C., Aldashev, A., Andersson, P., Andrighetto, G., Anum, A., Arikan, G., Aycan, Z., Bagherian, F., Barrera, D., Basnight-Brown, D., Batkeyev, B., Belaus, A., Berezina, E., Björnstjerna, M., Blumen, S., Boski, P., Zeineddine, F., Bovina, I., Huyen, B., Cardenas, J., Čekrlija, Đ., Choi, H., Contreras-Ibáñez, C., Costa-Lopes, R., de Barra, M., de Zoysa, P., Dorrough, A., Dvoryanchikov, N., Eller, A., Engelmann, J., Euh, H., Fang, X., Fiedler, S., Foster-Gimbel, O., Fülöp, M., Gardarsdottir, R., Gill, C., Glöckner, A., Graf, S., Grigoryan, A., Gritskov, V., Growiec, K., Halama, P., Hartanto, A., Hopthrow, T., Hřebíčková, M., Iliško, D., Imada, H., Kapoor, H., Kawakami, K., Khachatryan, N., Kharchenko, N., Khoury, N., Kiyonari, T., Kohút, M., Linh, L., Leslie, L., Li, Y., Li, N., Li, Z., Liik, K., Maitner, A., Manhique, B., Manley, H., Medhioub, I., Mentser, S., Mohammed, L., Nejat, P., Nipassa, O., Nussinson, R., Onyedire, N., Onyishi, I., Özden, S., Panagiotopoulou, P., Perez-Floriano, L., Persson, M., Pheko, M., Pirttilä-Backman, A., Pogosyan, M., Raver, J., Reyna, C., Rodrigues, R., Romanò, S., Romero, P., Sakki, I., Martin, A., Sherbaji, S., Shimizu, H., Simpson, B., Szabo, E., Takemura, K., Tieffi, H., Teixeira, M., Thanomkul, N., Tiliouine, H., Travaglino, G., Tsirbas, Y., Wan, R., Widodo, S., Zein, R., Zhang, Q., and Lange, L.

Published
2021

15. Perceptions of the appropriate response to norm violation in 57 societies

Author

Eriksson, K., Strimling, P., Gelfand, M., Wu, J., Abernathy, J., Akotia, C., Aldashev, A., Andersson, P., Andrighetto, G., Anum, A., Arikan, G., Aycan, Z., Bagherian, F., Barrera, D., Basnight-Brown, D., Batkeyev, B., Belaus, A., Berezina, E., Björnstjerna, M., Blumen, S., Boski, P., Zeineddine, F., Bovina, I., Huyen, B., Cardenas, J., Čekrlija, Đ., Choi, H., Contreras-Ibáñez, C., Costa-Lopes, R., de Barra, M., de Zoysa, P., Dorrough, A., Dvoryanchikov, N., Eller, A., Engelmann, J., Euh, H., Fang, X., Fiedler, S., Foster-Gimbel, O., Fülöp, M., Gardarsdottir, R., Gill, C., Glöckner, A., Graf, S., Grigoryan, A., Gritskov, V., Growiec, K., Halama, P., Hartanto, A., Hopthrow, T., Hřebíčková, M., Iliško, D., Imada, H., Kapoor, H., Kawakami, K., Khachatryan, N., Kharchenko, N., Khoury, N., Kiyonari, T., Kohút, M., Linh, L., Leslie, L., Li, Y., Li, N., Li, Z., Liik, K., Maitner, A., Manhique, B., Manley, H., Medhioub, I., Mentser, S., Mohammed, L., Nejat, P., Nipassa, O., Nussinson, R., Onyedire, N., Onyishi, I., Özden, S., Panagiotopoulou, P., Perez-Floriano, L., Persson, M., Pheko, M., Pirttilä-Backman, A., Pogosyan, M., Raver, J., Reyna, C., Rodrigues, R., Romanò, S., Romero, P., Sakki, I., Martin, A., Sherbaji, S., Shimizu, H., Simpson, B., Szabo, E., Takemura, K., Tieffi, H., Teixeira, M., Thanomkul, N., Tiliouine, H., Travaglino, G., Tsirbas, Y., Wan, R., Widodo, S., Zein, R., Zhang, Q., and Lange, L.

Published
2021

16. Psychometric Properties and Correlates of Precarious Manhood Beliefs in 62 Nations

Author

Bosson, J.K. Jurek, P. Vandello, J.A. Kosakowska-Berezecka, N. Olech, M. Besta, T. Bender, M. Hoorens, V. Becker, M. Timur Sevincer, A. Best, D.L. Safdar, S. Włodarczyk, A. Zawisza, M. Żadkowska, M. Abuhamdeh, S. Badu Agyemang, C. Akbaş, G. Albayrak-Aydemir, N. Ammirati, S. Anderson, J. Anjum, G. Ariyanto, A. Jamir Benzon R. Aruta, J. Ashraf, M. Bakaitytė, A. Bertolli, C. Bërxulli, D. Bi, C. Block, K. Boehnke, M. Bongiorno, R. Bosak, J. Casini, A. Chen, Q. Chi, P. Cubela Adoric, V. Daalmans, S. Dandy, J. Lemus, S.D. Dhakal, S. Dvorianchikov, N. Egami, S. Etchezahar, E. Sofia Esteves, C. Felix, N. Froehlich, L. Garcia-Sanchez, E. Gavreliuc, A. Gavreliuc, D. Gomez, Á. Guizzo, F. Graf, S. Greijdanus, H. Grigoryan, A. Grzymała-Moszczyńska, J. Guerch, K. Gustafsson Sendén, M. Hale, M.-L. Hämer, H. Hirai, M. Hoang Duc, L. Hřebíčková, M. Hutchings, P.B. Høj Jensen, D. Jasinskaja-Lahti, I. Karabati, S. Kelmendi, K. Kengyel, G. Khachatryan, N. Ghazzawi, R. Kinahan, M. Kirby, T.A. Kovács, M. Kozlowski, D. Krivoshchekov, V. Kulich, C. Kurosawa, T. Thi Lac An, N. Labarthe, J. Latu, I. Anne Lauri, M. Mankowski, E. Musbau Lawal, A. Li, J. Lindner, J. Lindqvist, A. Maitner, A.T. Makarova, E. Makashvili, A. Malayeri, S. Malik, S. Mancini, T. Manzi, C. Mari, S. Martiny, S.E. Mayer, C.-H. Mihić, V. Milošević Đorđević, J. Moreno-Bella, E. Moscatelli, S. Bryan Moynihan, A. Muller, D. Narhetali, E. Neto, F. Noels, K.A. Nyúl, B. O’Connor, E.C. Ochoa, D.P. Ohno, S. Olanrewaju Adebayo, S. Osborne, R. Giuseppina Pacilli, M. Palacio, J. Patnaik, S. Pavlopoulos, V. Pérez de León, P. Piterová, I. Barreiros Porto, J. Puzio, A. Pyrkosz-Pacyna, J. Rentería Pérez, E. Renström, E. Rousseaux, T. Ryan, M.K. Sainz, M. Salvati, M. Samekin, A. Schindler, S. Seydi, M. Shepherd, D. Sherbaji, S. Schmader, T. Simão, C. Sobhie, R. Souza, L.D. Sarter, E. Sulejmanović, D. Sullivan, K.E. Tatsumi, M. Tavitian-Elmadjian, L. Jain Thakur, S. Thi Mong Chi, Q. Torre, B. Torres, A. Torres, C.V. Türkoğlu, B. Ungaretti, J. Valshtein, T. Van Laar, C. van der Noll, J. Vasiutynskyi, V. Vauclair, C.-M. Venäläinen, S. Vohra, N. Walentynowicz, M. Ward, C. Yang, Y. Yzerbyt, V. Zanello, V. Ludmila Zapata-Calvente, A. Žukauskienė, R.

Abstract

Precarious manhood beliefs portray manhood, relative to womanhood, as a social status that is hard to earn, easy to lose, and proven via public action. Here, we present cross-cultural data on a brief measure of precarious manhood beliefs (the Precarious Manhood Beliefs scale [PMB]) that covaries meaningfully with other cross-culturally validated gender ideologies and with country-level indices of gender equality and human development. Using data from university samples in 62 countries across 13 world regions (N = 33,417), we demonstrate: (1) the psychometric isomorphism of the PMB (i.e., its comparability in meaning and statistical properties across the individual and country levels); (2) the PMB’s distinctness from, and associations with, ambivalent sexism and ambivalence toward men; and (3) associations of the PMB with nation-level gender equality and human development. Findings are discussed in terms of their statistical and theoretical implications for understanding widely-held beliefs about the precariousness of the male gender role. © The Author(s) 2021.

Published
2021

17. Author Correction: Perceptions of the appropriate response to norm violation in 57 societies (Nature Communications, (2021), 12, 1, (1481), 10.1038/s41467-021-21602-9)

Author

Eriksson, K. Strimling, P. Gelfand, M. Wu, J. Abernathy, J. Akotia, C.S. Aldashev, A. Andersson, P.A. Andrighetto, G. Anum, A. Arikan, G. Aycan, Z. Bagherian, F. Barrera, D. Basnight-Brown, D. Batkeyev, B. Belaus, A. Berezina, E. Björnstjerna, M. Blumen, S. Boski, P. Bou Zeineddine, F. Bovina, I. Huyen, B.T.T. Cardenas, J.-C. Čekrlija, Đ. Choi, H.-S. Contreras-Ibáñez, C.C. Costa-Lopes, R. de Barra, M. de Zoysa, P. Dorrough, A. Dvoryanchikov, N. Eller, A. Engelmann, J.B. Euh, H. Fang, X. Fiedler, S. Foster-Gimbel, O.A. Fülöp, M. Gardarsdottir, R.B. Gill, C.M.H.D. Glöckner, A. Graf, S. Grigoryan, A. Gritskov, V. Growiec, K. Halama, P. Hartanto, A. Hopthrow, T. Hřebíčková, M. Iliško, D. Imada, H. Kapoor, H. Kawakami, K. Khachatryan, N. Kharchenko, N. Khoury, N. Kiyonari, T. Kohút, M. Linh, L.T. Leslie, L.M. Li, Y. Li, N.P. Li, Z. Liik, K. Maitner, A.T. Manhique, B. Manley, H. Medhioub, I. Mentser, S. Mohammed, L. Nejat, P. Nipassa, O. Nussinson, R. Onyedire, N.G. Onyishi, I.E. Özden, S. Panagiotopoulou, P. Perez-Floriano, L.R. Persson, M.S. Pheko, M. Pirttilä-Backman, A.-M. Pogosyan, M. Raver, J. Reyna, C. Rodrigues, R.B. Romanò, S. Romero, P.P. Sakki, I. San Martin, A. Sherbaji, S. Shimizu, H. Simpson, B. Szabo, E. Takemura, K. Tieffi, H. Mendes Teixeira, M.L. Thanomkul, N. Tiliouine, H. Travaglino, G.A. Tsirbas, Y. Wan, R. Widodo, S. Zein, R. Zhang, Q.-P. Zirganou-Kazolea, L. Van Lange, P.A.M.

Abstract

The original version of this Article contained an error in the author affiliations. Cecilia Reyna was incorrectly associated with ‘Universidad Nacional de Córdoba (UNC). Facultad de Psicología (UNC), Ciudad Universitaria, Bv. de la Reforma esquina, Enfermera Gordillo s/n, Córdoba, Argentina.’ instead of the correct ‘Instituto de Investigaciones Psicológicas (IIPsi), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), CABA, República Argentina.’ This has now been corrected in both the PDF and HTML versions of the Article. © The Author(s) 2021

Published
2021

18. Structure of Dark Triad dirty dozen across eight world regions

Author

Rogoza, R., Żemojtel-Piotrowska, M., Jonason, P.K., Piotrowski, J., Campbell, K.W., Gebauer, J.E., Maltby, J., Sedikides, C., Adamovic, M., Adams, B.G., Ang, R.P., Ardi, R., Atitsogbe, K.A., Baltatescu, S., Bilić, S., Bodroža, B., Gruneau Brulin, J., Bundhoo Poonoosamy, H.Y., Chaleeraktrakoon, T., Del Carmen Dominguez, A., Dragova-Koleva, S., El-Astal, S., Eldesoki, W.L.M., Gouveia, V.V., Gundolf, K., Ilisko, D., Jukić, T., Kamble, S.V., Khachatryan, N., Klicperova-Baker, M., Kovacs, M., Kozytska, I., Larzabal Fernandez, A., Lehmann, K., Lei, X., Liik, K., McCain, J., Milfont, T.L., Nehrlich, A., Osin, E., Özsoy, E., Park, J., Ramos-Diaz, J., Riđić, O., Qadir, A., Samekin, A., Tiliouine, H., Tomsik, R., Umeh, C.S., van den Bos, K., Van Hiel, A., Vauclair, C.M., Włodarczyk, A., Empirical Legal Research (ELS), Empirical legal research into Institutions for conflict resolution, Bestuursrecht, Social-cognitive and interpersonal determinants of behaviour, Leerstoel Bos, Empirical Legal Research (ELS), Empirical legal research into Institutions for conflict resolution, Bestuursrecht, Social-cognitive and interpersonal determinants of behaviour, and Leerstoel Bos

Subjects
Male, CONCISE MEASURE, 050103 clinical psychology, Asia, Psychopathy, Culture, Social Sciences, 050109 social psychology, Ciências Sociais::Psicologia [Domínio/Área Científica], psychopathy, Taverne, Narcissism, psychopathy, Machiavellianism, Dark Triad, culture, measurement, Narcissism, medicine, Humans, Machiavellianism, 0501 psychology and cognitive sciences, Measurement invariance, VALIDITY, Applied Psychology, PERSONALITY, Measurement, Ciências Médicas::Medicina Básica [Domínio/Área Científica], Dark triad, Middle East, 05 social sciences, Antisocial Personality Disorder, medicine.disease, culture, BIFACTOR MODEL, Dark Triad, measurement, Europe, Clinical Psychology, PSYCHOMETRIC PROPERTIES, MEASUREMENT INVARIANCE, Dirty dozen, Western europe, North America, Female, medicine.symptom, Psychology, TRAITS, Demography
Abstract

The Dark Triad (i.e., narcissism, psychopathy, Machiavellianism) has garnered intense attention over the past 15 years. We examined the structure of these traits' measure-the Dark Triad Dirty Dozen (DTDD)-in a sample of 11,488 participants from three W.E.I.R.D. (i.e., North America, Oceania, Western Europe) and five non-W.E.I.R.D. (i.e., Asia, Middle East, non-Western Europe, South America, sub-Saharan Africa) world regions. The results confirmed the measurement invariance of the DTDD across participants' sex in all world regions, with men scoring higher than women on all traits (except for psychopathy in Asia, where the difference was not significant). We found evidence for metric (and partial scalar) measurement invariance within and between W.E.I.R.D. and non-W.E.I.R.D. world regions. The results generally support the structure of the DTDD. info:eu-repo/semantics/acceptedVersion

Published
2020

20. International Validation of a Methicillin-Resistant Staphylococcus aureusRisk Assessment Tool for Skin and Soft Tissue Infections

Author

Zasowski, E. J., Trinh, T. D., Claeys, K. C., Dryden, M., Shlyapnikov, S., Bassetti, M., Carnelutti, A., Khachatryan, N., Kurup, A., Pulido Cejudo, Abraham, Melo, L., Cao, B., and Rybak, Michael J.

Abstract

Introduction: To promote judicious prescribing of methicillin-resistant Staphylococcus aureus(MRSA)-active therapy for skin and soft tissue infections (SSTI), we previously developed an MRSA risk assessment tool. The objective of this study was to validate this risk assessment tool internationally. Methods: A multicenter, prospective cohort study of adults with purulent SSTI was performed at seven international sites from July 2016 to March 2018. Patient MRSA risk scores were computed as follows: MRSA infection/colonization history (2 points); previous hospitalization, previous antibiotics, chronic kidney disease, intravenous drug use, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), diabetes with obesity (1 point each). Predictive performance of MRSA surveillance percentage, MRSA risk score, and estimated MRSA probability (surveillance percentage adjusted by risk score) were quantified using the area under the receiver operating characteristic curves (aROC) and compared. Performance characteristics of different risk score thresholds across varying baseline MRSA prevalence were examined. Results: Two hundred three patients were included. Common SSTI were wounds (28.6%), abscess (25.1%), and cellulitis with abscess (20.7%). Patients with higher risk scores were more likely to have MRSA (P< 0.001). The MRSA risk score aROC (95%CI) [0.748 (0.678–0.819)] was significantly greater than MRSA surveillance percentage [0.646 (0.569–0.722)] (P= 0.016). Estimated MRSA probability aROC [0.781 (0.716–0.845)] was significantly greater than surveillance percentage (P< 0.001) but not the risk score (P= 0.192). The estimated negative predictive value (NPV) of an MRSA score ≥ 1 (i.e., a score of 0) was greater than 90% when MRSA prevalence was 30% or less. Conclusion: The MRSA risk score and estimated MRSA probability were significantly more predictive of MRSA compared with surveillance percentage. An MRSA risk score of zero had high predictive value and could help avoid unnecessary empiric MRSA coverage in low-acuity patients. Further study, including impact of such risk assessment tools on prescribing patterns and outcomes are required before implementation.

Published
2022
Full Text
View/download PDF

21. Country-level and individual-level predictors of men's support for gender equality in 42 countries

Author

Kosakowska-Berezecka, N. Besta, T. Bosson, J.K. Jurek, P. Vandello, J.A. Best, D.L. Wlodarczyk, A. Safdar, S. Zawisza, M. Żadkowska, M. Sobiecki, J. Agyemang, C.B. Akbaş, G. Ammirati, S. Anderson, J. Anjum, G. Aruta, J.J.B.R. Ashraf, M. Bakaitytė, A. Bi, C. Becker, M. Bender, M. Bërxulli, D. Bosak, J. Daalmans, S. Dandy, J. de Lemus, S. Dvorianchikov, N. Etchezahar, E. Froehlich, L. Gavreliuc, A. Gavreliuc, D. Gomez, Á. Greijdanus, H. Grigoryan, A. Hale, M.-L. Hämer, H. Hoorens, V. Hutchings, P.B. Jensen, D.H. Kelmendi, K. Khachatryan, N. Kinahan, M. Kozlowski, D. Lauri, M.A. Li, J. Maitner, A.T. Makashvili, A. Mancini, T. Martiny, S.E. Đorđević, J.M. Moreno-Bella, E. Moscatelli, S. Bryan Moynihan, A. Muller, D. Ochoa, D. Adebayo, S.O. Pacilli, M.G. Palacio, J. Patnaik, S. Pavlopoulos, V. Piterová, I. Puzio, A. Pyrkosz-Pacyna, J. Rentería-Pérez, E. Rousseaux, T. Sainz, M. Salvati, M. Samekin, A. García-Sánchez, E. Schindler, S. Sherbaji, S. Sobhie, R. Sulejmanović, D. Sullivan, K.E. Torre, B. Torres, C.V. Ungaretti, J. Valshtein, T. Van Laar, C. van der Noll, J. Vasiutynskyi, V. Vohra, N. Zapata-Calvente, A.L. Žukauskienė, R.

Abstract

Men sometimes withdraw support for gender equality movements when their higher gender status is threatened. Here, we expand the focus of this phenomenon by examining it cross-culturally, to test if both individual- and country-level variables predict men's collective action intentions to support gender equality. We tested a model in which men's zero-sum beliefs about gender predict reduced collective action intentions via an increase in hostile sexism. Because country-level gender equality may threaten men's higher gender status, we also examined whether the path from zero-sum beliefs to collective action intentions was stronger in countries higher in gender equality. Multilevel modeling on 6,734 men from 42 countries supported the individual-level mediation model, but found no evidence of moderation by country-level gender equality. Both country-level gender equality and individual-level zero-sum thinking independently predicted reductions in men's willingness to act collectively for gender equality. © 2020 John Wiley & Sons, Ltd.

Published
2020

23. Introducing new and repurposed TB drugs: the endTB experience

Author

Seung, K. J., primary, Khan, U., additional, Varaine, F., additional, Ahmed, S., additional, Bastard, M., additional, Cloez, S., additional, Damtew, D., additional, Franke, M. F., additional, Herboczek, K., additional, Huerga, H., additional, Islam, S., additional, Karakozian, H., additional, Khachatryan, N., additional, Kliesckova, J., additional, Khan, A. J., additional, Khan, M., additional, Khan, P., additional, Kotrikadze, T., additional, Lachenal, N., additional, Lecca, L., additional, Lenggogeni, P., additional, Maretbayeva, S., additional, Melikyan, N., additional, Mesic, A., additional, Mitnick, C. D., additional, Mofolo, M., additional, Perrin, C., additional, Richard, M., additional, Tassew, Y. M., additional, Telnov, A., additional, Vilbrun, S. C., additional, Wanjala, S., additional, Rich, M. L., additional, and Hewison, C., additional

Published
2020
Full Text
View/download PDF

29. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients

Author

Legkonogov, O., Ramacciotti, E., Mikhailova, E., Koryk, V., Adzerikho, I., Schoenerr, H., Mathies, R., Konig, J., Huber, K., Rubinfeld, A., Finfer, S., Manenti, E., Bott, M., Blessing, E., Beyer-Westendorf, J., Coughlin, P., Baker, R., Poy, C., Dengler, T., Parody, M., Oliva, M., Macin, S., Jure, H., Ferrari, A. E., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Mitkovskaya, N., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Tiefenbacher, C., Weimar, C., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Berrouschot, J., Kirschner, R., Amann, B., Paposhvili, K., Pagava, Z., Kristof, P., Lakatos, F., Laszlo, Z., Freire, A., Lupkovics, G., Megreladze, I., Kobulia, B., Khintibidze, I., Khabeishvili, G., Datikashvili-David, I., Simoneau, G., Merkely, B., Andras, C. Nagy, Nemeth, L., Papp, A., Soltesz, P., Fiss, E., Schmidt, J., Roy, P-M., Quere, I., Proust, A., Pottier, P., Pernod, G., Payot, L., Bizzacchi, J. Annichino, Lienart, F., Paleiron, N., Montaclair, K., Mismetti, P., Messas, E., Lacroix, P., Grange, C., Falvo, N., El Kouri, D., Decoulx, E., Debourdeau, P., De Geeter, G., Brisot, D., Belhassane, A., Aquilanti, S., Agraou, B., Vikman, S., Tatlisumak, T., Saarinen, J., Kaaja, R., Honkaniemi, J., Airaksinen, J., Uuetoa, T., Lember, M., Urhammer, S., Tuxen, C., Storgaard, M., Lassen, M., Christensen, H., Vyhnanek, M., Vejvoda, J., Spacek, R., Reiterer, P., Podpera, I., Mikulova, J., Lang, P., Jajtner, P., Hubac, J., Horny, I., Holaj, R., Herold, M., Havelka, J., Francek, L., Dusek, J., Dunaj, M., Cizek, V., Chochola, J., Chlumsky, J., Cermak, O., Skerk, V., Vagic, J. Sikic, Marusic, S., Knezevic, A., Kalinic-Grgorinic, H., Jakopovic, M., Francetic, I., Ciglenecki, N., Car, S., Butkovic-Soldo, S., Cardenas, S. Potthoff, Lazcano, M. Opazo, Alarcon, M. Arias, Verreault, S., Provencher, S., Pearce, M., Le Gal, G., Douketis, J., Dhar, A., Tokmakova, M., Todorov, G., Syulemzova, S., Raymuno, S., Rocha, A., Dimov, B., Grigorov, M., Kalpachki, R., Kamenova, Z., Bello, F., Harrington, Robert A., Bandman, Olga, Kostadinova, M., Milanova, M., Dive, A., Pencheva, G., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Delforge, M., Vertes, A., Efrati, S., Elias, M., Gafter, A., Nazliel, BİJEN, Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, R., Runev, N., Lembo, G., Lodigiani, C., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Stoeva, N., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Gold, Alex, Visona, A., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Stoyanov, M., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Castillo Leon, R., Pimanov, S., Polonetsy, L., Pereyra, R. Cotrina, Karlo, L. Farjardo, Horna, M., Soroka, N., Salas, M., Yanez, L. Toche, Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Walasek, L., Blockmans, D., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Musetescu, R., Podoleanu, C., Popescu, M., Stamate, S., Stanciulescu, G., Vida-Simiti, L., Abashev, A., Andreev, D., Apartsin, K., Arkhipov, M., Averkov, O., Barbarash, O., Belskaya, G., Bogdanov, E., Boldueva, S., Chefranova, Z., Dovgalevskiy, Y., Ershova, O., Goloshchekin, B., Khachatryan, N., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Malygin, A., Martynenko, T., Martynenko, V., Maslova, N., Mordovin, V., Nikolaev, K., Nilk, R., Popov, D., Privalova, E., Reshetko, O., Shapovalova, Y., Shpagina, L., Shvarts, Y., Simanenkov, V., Solovyov, O., Vishneva, E., Vishnevskiy, A., Apostolovic, S., Celic, V., Ilic, S., Kovacevic-Kuzmanovic, A., Miloradovic, V., Bodikova, S., Cervenakova, A., Dvorak, M., Herman, O., Hrubon, A., Kokles, M., Krastev, G., Payer, J., Prokop, D., Spisakova, M., Adler, D., Basson, M., Breedt, J., Engelbrecht, J., Mitha, I., Van Dyk, C., Alvarez Sala, L. A., Barbagelata Lopez, C., Bisbe, J., Castro Guardiola, A., Cepeda, J. M., Cereto, F., Diaz Santos, E., Ferrer, R., Gomez Cerezo, J., Hernandez, Adrian F., Gonzales-Porras, J. R., Grandes, J., Cohen, Alexander T., Gibson, C. Michael, Chi, Gerald, Halaby, Rim, Korjian, Serge, Daaboul, Yazan, Jain, Purva, Arbetter, Douglas, Goldhaber, Samuel Z., Hull, Russel, Jimenez, D., Mellibovsky, L., Richart, C., Riera, A., Trujillo, J., Vargas Nunez, J. A., Villalta, J., Akgul, O., Guneri, S., Kilichesmez, K., Kirma, C., Kutluk, H., Okumus, G., Tigen, K., Topcuoglu, M., Tuncay, E., Abrahamovych, O., Batushkin, V., Brozhyk, J., Burmak, I., Godlevska, O., Goloborodko, A., Goloborodko, B., Goncharova, Y., Gryb, V., Karpenko, O., Kopytsya, M., Zakai, N., Yousef, K., Wichman, T., Whitman, B., Welker, J., Welch, M., Warner, A., Updegrove, J., Tuck, M., Stoltz, S., Sokol, S., Sharma, S., Shammas, N., Saba, F., Rodriguez, W., Rees, C., Rastogi, P., Rajan, R., Quintana, O., Pullman, J., Pratt, R., Pineda, L., Pearl, R., Parthiban, K., Overcash, J., Ortel, T., Ohaju, V., Nadar, V., Mittal, M., Milling, T., McLaren, G., Margolis, B., Mahal, S., Macchiavelli, A., Lopez, J., Lerner, R., Kung, M., Kouras, F., Kazimir, M., Kao, C-K., Kabler, H., Ioachimescu, O., Hazelrigg, M., Hamad, A., Haidar, A., Hahn, B., Goytia-Leos, D., Gaggin, H., Fulmer, J., Koshlia, V., Fraiz, J., Krakhmalova, O., Fermann, G., Farley, B., Doshi, A., Dhingra, R., Cornell, J., Concha, M., Clark, C., Chang, H., Carman, T., Bidair, M., Bercz, P., Bastani, A., Barney, J., Baker, S., Anderson, C., Amin, M., Almasri, E., Natarajan, I., McCollum, C., MacCallum, P., Davis, M., Body, R., Yagensky, A., Voronkov, L., Vishnivestsky, I., Vakaliuk, I., Ursol, G., Tseluyko, V., Kyrychenko, I., Svyshchenko, Y., Svyridova, I., Ryabichenko, T., Rudenko, L., Reshotko, D., Perepeliuk, M., Parkhomenko, O., Nikonov, V., Maslovaskyi, V., Malynovsky, Y., Sergeeva, E., and Kolman, P.

Subjects
Male, medicine.medical_specialty, Pyridines, Intracranial Hemorrhages, 030204 cardiovascular system & hematology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Medical illness, Physiology (medical), medicine, Humans, 030212 general & internal medicine, Enoxaparin, Intensive care medicine, Stroke, Aged, business.industry, Anticoagulants, Venous Thromboembolism, medicine.disease, Thrombosis, chemistry, Betrixaban, Benzamides, Emergency medicine, Female, Cardiology and Cardiovascular Medicine, business, Complication, Venous thromboembolism
Abstract

Background: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Methods: Hospitalized acutely medically ill subjects (n=7513) were randomized in a double-dummy double-blind fashion to either extended-duration oral betrixaban (80 mg once daily for 35–42 days) or standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days) for venous thromboprophylaxis. Stroke events were adjudicated by an independent, blinded event adjudication committee. Results: The mean age of study participants was 76 years; 45% were male; 13% had had a stroke; and 45% had congestive heart failure. There were fewer all-cause strokes (0.54% versus 0.97%; relative risk [RR]=0.56; 95% confidence interval, 0.32–0.96; P =0.032; adjusted RR=0.43%; number needed to treat=233) and ischemic strokes (0.48% versus 0.91%; RR=0.53; 95% confidence interval, 0.30–0.94; P =0.026; adjusted RR=0.43%; number needed to treat=233) among patients treated with betrixaban versus enoxaparin through 77 days of follow-up. Among high-risk subjects, those with congestive heart failure or ischemic stroke as their index event, betrixaban reduced the risk of all-cause stroke (0.72% versus 1.48%; RR=0.49; 95% confidence interval, 0.26–0.90; P =0.019; adjusted RR=0.76%; number needed to treat=132) and ischemic stroke (0.63% versus 1.38%; RR=0.45; 95% confidence interval, 0.24–0.87; P =0.014; adjusted RR=0.75%; number needed to treat=134) compared with enoxaparin. Conclusions: Among hospitalized medically ill patients, extended-duration betrixaban significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01583218.

Published
2017

30. ANTIBACTERIAL PROPERTIES OF NEW CHITOSAN-BASED SCHIFF BASES

Author

G. E. Khachatryan N. I. Mkrtchyan and V. B. Gavalyan.

Subjects
antibacterial activity chitosan chitosan-based Schiff base
Abstract

Chitosan, a derivative of chitin, one of the most widespread natural polysaccharides, is of great interest in terms of practical application. The importance of this polymer and its derivatives cannot be overestimated since it is currently used in such spheres of human activity as medicine, agriculture, food and textile industries, nuclear medicine, pharmaceutics and cosmetology, ecology and others. Its antibacterial properties are of particular interest. In the A.I. Alikhanyan National Science Laboratory Foundation (Yerevan Physics Institute) the works are being conducted on obtaining/synthesizing new samples of chitosan Schiff bases. The present work is devoted to the study of the antibacterial activity of newly synthesized Schiff bases derivatives of chitosan. As test cultures in studying their antibacterial properties, several aerobic gram-negative and one gram-positive bacteria were used. It has been reliably shown that at least a two of the five samples of chitosan and its derivatives studied by us had pronounced antibacterial properties. The effectiveness of the preparations impact differed from culture to culture. Of all the cultures tested, the wild type of the bacterial culture of Bacillus cereus proved to be the most sensitive. The term ?effective ratio? (ER) is proposed for the shift of selected ratios one way or another, which resulted either in a complete stop of cell proliferation or cessation of the chitosan derivative to affect the ability of cells to reproduce.

Published
2018
Full Text
View/download PDF

34. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy

Author

Gibson, C. M., Korjian, S., Chi, G., Daaboul, Y., Jain, P., Arbetter, D., Goldhaber, S. Z., Hull, R., Hernandez, A. F., Lopes, R. D., Gold, A., Cohen, A. T., Harrington, R. A., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Oliva, M., Parody, M., Poy, C., Baker, R., Colquhoun, D., Coughlin, P., Finfer, S., Hammerschlag, G., Rubinfeld, A., Huber, K., Konig, J., Mathies, R., Pilger, E., Schoenerr, H., Adzerikho, I., Koryk, V., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Polonetsy, L., Soroka, N., Blockmans, D., Delforge, M., Dive, A., Lienart, F., Motte, S., Annichino Bizzacchi, J., Fiss, E., Freire, A., Manenti, E., Ramacciotti, E., Raymuno, S., Rocha, A., Saraiva, J. F., Dimov, B., Grigorov, M., Kalpachki, R., Kamenova, Z., Kostadinova, M., Milanova, M., Mincheva, V., Pencheva, G., Raev, D., Runev, N., Stoeva, N., Stoyanov, M., Syulemzova, S., Todorov, G., Tokmakova, M., Dhar, A., Douketis, J., Kahn, S., Le Gal, G., Pearce, M., Provencher, S., Verreault, S., Arias Alarcon, M., Olivares Canon, C., Opazo Lazcano, M., Potthoff Cardenas, S., Butkovic-Soldo, S., Car, S., Ciglenecki, N., Francetic, I., Jakopovic, M., Kalinic-Grgorinic, H., Knezevic, A., Malojcic, B., Marusic, S., Sikic Vagic, J., Skerk, V., Cermak, O., Cervinka, P., Chlumsky, J., Chochola, J., Cizek, V., Dunaj, M., Dusek, J., Francek, L., Havelka, J., Herold, M., Holaj, R., Horny, I., Hubac, J., Jajtner, P., Kolman, P., Lang, P., Mayer, O., Mikulova, J., Podpera, I., Reiterer, P., Spacek, R., Vejvoda, J., Vyhnanek, M., Christensen, H., Lassen, M., Storgaard, M., Tuxen, C., Urhammer, S., Lember, M., Marandi, T., Uuetoa, T., Airaksinen, J., Honkaniemi, J., Kaaja, R., Lassila, R., Saarinen, J., Tatlisumak, T., Vikman, S., Agraou, B., Aquilanti, S., Belhassane, A., Brisot, D., De Geeter, G., Debourdeau, P., Decoulx, E., El Kouri, D., Falvo, N., Grange, C., Lacroix, P., Messas, E., Mismetti, P., Montaclair, K., Mottier, D., Paleiron, N., Payot, L., Pernod, G., Pottier, P., Proust, A., Quere, I., Roy, P. -M., Schmidt, J., Simoneau, G., Datikashvili-David, I., Khabeishvili, G., Khintibidze, I., Kobulia, B., Megreladze, I., Pagava, Z., Paposhvili, K., Shaburishvili, T., Amann, B., Berrouschot, J., Beyer-Westendorf, J., Blessing, E., Bott, M., Dengler, T., Diehm, C., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Schellong, S., Schmidt-Lucke, J., Singer, C., Tiefenbacher, C., Veltkamp, R., Weimar, C., Zeymer, U., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Kirschner, R., Kristof, P., Lakatos, F., Laszlo, Z., Lupkovics, G., Merkely, B., Nagy Andras, C., Nemeth, L., Papp, A., Soltesz, P., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Vertes, A., Efrati, S., Elias, M., Gafter, A., Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Zeltser, D., Ageno, W., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, R., Lembo, G., Lodigiani, C., Luisetti, M., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Visona, A., Krievins, D., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Bagdonas, A., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Castillo Leon, R., Cotrina Pereyra, R., Farjardo Karlo, L., Horna, M., Lema Osores, J., Salas, M., Toche Yanez, L., Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Tomkowski, W., Walasek, L., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Mot, S., Musetescu, R., Podoleanu, C., Popescu, M., Stamate, S., Stanciulescu, G., Vida-Simiti, L., Abashev, A., Andreev, D., Apartsin, K., Arkhipov, M., Averkov, O., Barbarash, O., Belskaya, G., Bogdanov, E., Boldueva, S., Chefranova, Z., Dovgalevskiy, Y., Ershova, O., Goloshchekin, B., Khachatryan, N., Khurs, E., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Malygin, A., Martynenko, T., Martynenko, V., Maslova, N., Mordovin, V., Nikolaev, K., Nilk, R., Panchenko, E., Popov, D., Privalova, E., Reshetko, O., Sergeeva, E., Shapovalova, Y., Shpagina, L., Shvarts, Y., Simanenkov, V., Solovyov, O., Vishneva, E., Vishnevskiy, A., Apostolovic, S., Celic, V., Ilic, S., Kovacevic-Kuzmanovic, A., Miloradovic, V., Tan, R. S., Bodikova, S., Cervenakova, A., Dvorak, M., Gaspar, L., Herman, O., Hrubon, A., Kokles, M., Krastev, G., Payer, J., Prokop, D., Spisakova, M., Adler, D., Basson, M., Breedt, J., Engelbrecht, J., Jacobson, B., Mitha, I., Van Dyk, C., Alvarez Sala, L. A., Barbagelata Lopez, C., Bisbe, J., Castro Guardiola, A., Cepeda, J. M., Cereto, F., Diaz Santos, E., Ferrer, R., Gomez Cerezo, J., Gonzales-Porras, J. R., Grandes, J., Jimenez, D., Martin Loeches, I., Mellibovsky, L., Richart, C., Riera, A., Trujillo, J., Vargas Nunez, J. A., Villalta, J., Akgul, O., Guneri, S., Kilichesmez, K., Kirma, C., Kutluk, H., Nazliel, B., Okumus, G., Ongen, G., Tigen, K., Topcuoglu, M., Tuncay, E., Abrahamovych, O., Batushkin, V., Brozhyk, J., Burmak, I., Godlevska, O., Goloborodko, A., Goloborodko, B., Goncharova, Y., Gryb, V., Karpenko, O., Kopytsya, M., Koshlia, V., Krakhmalova, O., Kyrychenko, I., Legkonogov, O., Malynovsky, Y., Maslovaskyi, V., Nikonov, V., Parkhomenko, O., Perepeliuk, M., Reshotko, D., Rudenko, L., Ryabichenko, T., Svyridova, I., Svyshchenko, Y., Tseluyko, V., Ursol, G., Vakaliuk, I., Vishnivestsky, I., Voronkov, L., Yagensky, A., Body, R., Chandra, D., Davis, M., Kesteven, P., Maccallum, P., Mccollum, C., Natarajan, I., Almasri, E., Amin, M., Anderson, C., Baker, S., Barney, J., Bastani, B. B. A., Bercz, P., Bidair, M., Carman, T., Chang, H., Clark, C., Concha, M., Cornell, J., Dhingra, R., Doshi, A., Ebrahimi, R., Farley, B., Fermann, G., Foster, G., Fraiz, J., Fulmer, J., Gaggin, H., Goytia-Leos, D., Hahn, B., Haidar, A., Hamad, A., Hazelrigg, M., Ioachimescu, O., Johnson, B., Kabler, H., Kao, C. -K., Kazimir, M., Kouras, F., Kung, M., Lerner, R., Lopez, J., Macchiavelli, A., Mahal, S., Margolis, B., Mclaren, G., Milling, T., Mittal, M., Nadar, V., Ohaju, V., Ortel, T., Overcash, J., Parthiban, K., Pearl, R., Pineda, L., Pratt, R., Pullman, J., Quintana, O., Rajan, R., Rastogi, P., Rees, C., Rodriguez, W., Saba, F., Shammas, N., Sharma, S., Sokol, S., Stoltz, S., Subich, D., Tuck, M., Updegrove, J., Warner, A., Welch, M., Welker, J., Whitman, B., Wichman, T., Yousef, K., Yusen, R., and Zakai, N.

Subjects
Male, pulmonary embolism, Time Factors, Pyridines, Intracranial hemorrhage, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Risk Factors, Clinical Studies, Medicine, 030212 general & internal medicine, Myocardial infarction, Original Research, Ischemic stroke, Hazard ratio, Absolute risk reduction, Venous Thromboembolism, Middle Aged, Interventional Cardiology, Pulmonary embolism, Death, myocardial infarction, Treatment Outcome, Cardiovascular Diseases, Anesthesia, Acute Disease, Benzamides, Number needed to treat, Female, Cardiology and Cardiovascular Medicine, Intracranial Hemorrhages, Adult, venous thromboembolism, Hemorrhage, 03 medical and health sciences, Double-Blind Method, death, ischemic stroke, Humans, Enoxaparin, Aged, Proportional Hazards Models, Inpatients, Venous thromboembolism, business.industry, Settore MED/09 - MEDICINA INTERNA, Anticoagulants, Thrombosis, medicine.disease, Clinical trial, chemistry, Betrixaban, business, Acute Coronary Syndromes, intracranial hemorrhage, Factor Xa Inhibitors
Abstract

Background Extended‐duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm. Methods and Results This was a post hoc analysis of the APEX trial—a multicenter, double‐blind, randomized controlled trial comparing extended‐duration betrixaban versus standard‐of‐care enoxaparin. A composite of all fatal or irreversible safety (fatal bleeding or intracranial hemorrhage) and efficacy events (cardiopulmonary death, myocardial infarction, pulmonary embolism, and ischemic stroke) was evaluated in a time‐to‐first event analysis. In patients with positive D‐dimer results, betrixaban reduced fatal or irreversible events at 35 to 42 days (4.80% versus 3.54%; hazard ratio, 0.73; absolute risk reduction, 1.26%; number needed to treat, 79 [ P =0.033]) and at study end at 77 days (6.27% versus 4.36%; hazard ratio, 0.70; absolute risk reduction, 1.91%; number needed to treat, 52 [ P =0.005]) versus enoxaparin. In all patients, betrixaban reduced fatal or irreversible events at 35 to 42 days (4.08% versus 2.90%; hazard ratio, 0.71; absolute risk reduction, 1.18%; number needed to treat, 86 [ P =0.006]) and 77 days (5.17% versus 3.64%; hazard ratio, 0.70; absolute risk reduction, 1.53%; number needed to treat, 65 [ P =0.002]). Conclusions Among hospitalized medically ill patients, extended‐duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard‐duration enoxaparin. A total of 65 patients would require treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin. Clinical Trial Registration URL : http://www.ClinicalTrials.gov . Unique identifier: NCT 01583218.

Published
2017

35. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

Author

Hewison, C., primary, Bastard, M., additional, Khachatryan, N., additional, Kotrikadze, T., additional, Hayrapetyan, A., additional, Avaliani, Z., additional, Kiria, N., additional, Yegiazaryan, L., additional, Chumburidze, N., additional, Kirakosyan, O., additional, Atshemyan, H., additional, Qayyum, S., additional, Lachenal, N., additional, Varaine, F., additional, and Huerga, H., additional

Published
2018
Full Text
View/download PDF

36. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

Author

Raymuno, S., Ramacciotti, E., Manenti, E., Freire, A., Fiss, E., Bizzacchi, J. Annichino, Lienart, F., Dive, A., Delforge, M., Blockmans, D., Soroka, N., Kamenova, Z., Kostadinova, M., Milanova, M., Pencheva, G., Runev, N., Stoeva, N., Stoyanov, M., Syulemzova, S., Todorov, G., Polonetsy, L., Pimanov, S., Mitkovskaya, N., Tokmakova, M., Dhar, A., Mikhailova, E., Koryk, V., Adzerikho, I., Schoenerr, H., Mathies, R., Douketis, J., Konig, J., Le Gal, G., Pearce, M., Provencher, S., Verreault, S., Alarcon, M. Arias, Lazcano, M. Opazo, Cardenas, S. Potthoff, Butkovic-Soldo, S., Car, S., Ciglenecki, N., Francetic, I., Jakopovic, M., Kalinic-Grgorinic, H., Knezevic, A., Marusic, S., Vagic, J. Sikic, Skerk, V., Cermak, O., Gibson, C. Michael, Halaby, Rim, Korjian, Serge, Daaboul, Yazan, Arbetter, Douglas F., Yee, Megan K., Chlumsky, J., Chochola, J., Cizek, V., Goldhaber, Samuel Z., Hull, Russel, Hernandez, Adrian F., Huber, K., Lu, Shiao-ping, Dunaj, M., Dusek, J., Francek, L., Havelka, J., Herold, M., Holaj, R., Nazliel, BİJEN, Bandman, Olga, Leeds, Janet M., Gold, Alex, Harrington, Robert A., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Oliva, M., Parody, M., Horny, I., Hubac, J., Jajtner, P., Kolman, P., Poy, C., Baker, R., Lang, P., Mikulova, J., Podpera, I., Reiterer, P., Spacek, R., Vejvoda, J., Vyhnanek, M., Christensen, H., Lassen, M., Storgaard, M., Tuxen, C., Urhammer, S., Lember, M., Uuetoa, T., Airaksinen, J., Honkaniemi, J., Kaaja, R., Saarinen, J., Tatlisumak, T., Vikman, S., Agraou, B., Aquilanti, S., Belhassane, A., Brisot, D., De Geeter, G., Coughlin, P., Finfer, S., Debourdeau, P., Decoulx, E., El Kouri, D., Falvo, N., Grange, C., Rubinfeld, A., Lacroix, P., Messas, E., Mismetti, P., Montaclair, K., Paleiron, N., Payot, L., Zakai, N., Yousef, K., Wichman, T., Whitman, B., Welker, J., Welch, M., Warner, A., Updegrove, J., Tuck, M., Stoltz, S., Sokol, S., Sharma, S., Shammas, N., Saba, F., Rodriguez, W., Rastogi, P., Rajan, R., Quintana, O., Pullman, J., Pratt, R., Pineda, L., Pernod, G., Pearl, R., Parthiban, K., Ortel, T., Ohaju, V., Pottier, P., Proust, A., Quere, I., Roy, P-M., Schmidt, J., Simoneau, G., Datikashvili-David, I., Khabeishvili, G., Khintibidze, I., Nadar, V., Mittal, M., Milling, T., McLaren, G., Margolis, B., Mahal, S., Macchiavelli, A., Lopez, J., Lerner, R., Kung, M., Kouras, F., Kazimir, M., Kao, C-K., Kabler, H., Ioachimescu, O., Hazelrigg, M., Hamad, A., Haidar, A., Hahn, B., Goytia-Leos, D., Gaggin, H., Fulmer, J., Fraiz, J., Fermann, G., Farley, B., Doshi, A., Dhingra, R., Cornell, J., Concha, M., Clark, C., Chang, H., Carman, T., Bidair, M., Bercz, P., Bastani, A., Barney, J., Baker, S., Anderson, C., Amin, M., Almasri, E., Natarajan, I., McCollum, C., MacCallum, P., Davis, M., Body, R., Yagensky, A., Voronkov, L., Vishnivestsky, I., Vakaliuk, I., Ursol, G., Tseluyko, V., Svyshchenko, Y., Svyridova, I., Ryabichenko, T., Rudenko, L., Reshotko, D., Perepeliuk, M., Parkhomenko, O., Nikonov, V., Maslovaskyi, V., Malynovsky, Y., Legkonogov, O., Kyrychenko, I., Krakhmalova, O., Koshlia, V., Kopytsya, M., Karpenko, O., Gryb, V., Goncharova, Y., Goloborodko, B., Goloborodko, A., Godlevska, O., Burmak, I., Brozhyk, J., Batushkin, V., Abrahamovych, O., Tuncay, E., Topcuoglu, M., Tigen, K., Okumus, G., Kutluk, H., Kirma, C., Kilichesmez, K., Guneri, S., Akgul, O., Villalta, J., Vargas Nunez, J. A., Trujillo, J., Riera, A., Richart, C., Mellibovsky, L., Jimenez, D., Grandes, J., Gonzales-Porras, J. R., Gomez Cerezo, J., Ferrer, R., Diaz Santos, E., Cereto, F., Cepeda, J. M., Castro Guardiola, A., Bisbe, J., Barbagelata Lopez, C., Alvarez Sala, L. A., Van Dyk, C., Mitha, I., Engelbrecht, J., Breedt, J., Basson, M., Adler, D., Spisakova, M., Payer, J., Krastev, G., Kokles, M., Hrubon, A., Herman, O., Dvorak, M., Cervenakova, A., Bodikova, S., Miloradovic, V., Kovacevic-Kuzmanovic, A., Ilic, S., Celic, V., Apostolovic, S., Vishnevskiy, A., Vishneva, E., Solovyov, O., Simanenkov, V., Shvarts, Y., Shpagina, L., Shapovalova, Y., Sergeeva, E., Reshetko, O., Privalova, E., Popov, D., Nilk, R., Nikolaev, K., Mordovin, V., Maslova, N., Martynenko, V., Martynenko, T., Malygin, A., Kostenko, V., Kosmacheva, E., Kobalava, Z., Klein, G., Khachatryan, N., Ershova, O., Dovgalevskiy, Y., Chefranova, Z., Boldueva, S., Bogdanov, E., Belskaya, G., Barbarash, O., Averkov, O., Arkhipov, M., Apartsin, K., Andreev, D., Abashev, A., Vida-Simiti, L., Stanciulescu, G., Stamate, S., Kobulia, B., Megreladze, I., Pagava, Z., Paposhvili, K., Amann, B., Beyer-Westendorf, J., Blessing, E., Bott, M., Dengler, T., Dziewas, R., Genth-Zotz, S., Hamann, F., Horacek, T., Klimpe, S., Kroning, R., Lapp, H., Lawall, H., Licka, M., Rizos, T., Tiefenbacher, C., Weimar, C., Alkonyi, B., Falukozy, J., Futo, L., Katona, A., Kirschner, R., Kristof, P., Lakatos, F., Lupkovics, G., Merkely, B., Andras, C. Nagy, Nemeth, L., Papp, A., Soltesz, P., Sudar, Z., Szabo, G., Szegedi, N., Timar, G., Valco, J., Vertes, A., Efrati, S., Elias, M., Gafter, A., Hayek, T., Hussein, O., Lishner, M., Lugassy, G., Cerveri, I., D'Angelo, A., De Pellegrin, A., Imberti, D., Landolfi, R., Lembo, G., Lodigiani, C., Moia, M., Molteni, M., Mumoli, N., Novo, S., Orlandini, F., Parisi, R., Pizzini, A., Pomero, F., Salvi, A., Schenone, A., Visona, A., Martinova, V., Pontaga, N., Rozitis, V., Stukena, I., Alekniene, B., Basijokiene, V., Butkiene, Z., Griskeviciene, V., Naudziunas, A., Norvaisiene, R., Norviliene, R., Petrauskiene, R., Poskiene, R., Susinskiene, D., Valavicius, A., Castillo Leon, R., Pereyra, R. Cotrina, Karlo, L. Farjardo, Horna, M., Salas, M., Yanez, L. Toche, Fryze, W., Gaciong, Z., Gniot, J., Gorecka, D., Gruenpeter, P., Grzelakowski, P., Jastrzebski, D., Kucharski, L., Mirek-Bryniarska, E., Pulkowski, G., Sobkowicz, B., Sulik, P., Walasek, L., Waldemar, K., Wrzesinski, K., Balogh, Z. E., Bojinca, M., Marin, I., Musetescu, R., Podoleanu, C., Popescu, M., Kalpachki, R., Grigorov, M., Dimov, B., Rocha, A., Goloshchekin, B., Berrouschot, J., Laszlo, Z., Rees, C., Overcash, J., Prokop, D., and Cohen, Alexander T.

Subjects
Relative risk reduction, Male, Pyridines, Population, Hemorrhage, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacokinetics, Randomized controlled trial, Double-Blind Method, law, Medicine, Humans, 030212 general & internal medicine, Dosing, Enoxaparin, education, Aged, Aged, 80 and over, Venous Thrombosis, education.field_of_study, business.industry, Absolute risk reduction, Anticoagulants, Venous Thromboembolism, Hospitalization, chemistry, Concomitant, Betrixaban, Anesthesia, Benzamides, Female, Cardiology and Cardiovascular Medicine, business, Pulmonary Embolism, Factor Xa Inhibitors
Abstract

The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor.This analysis assessed the pharmacokinetics, efficacy, and safety of full- (80 mg) and reduced-dose (40 mg) betrixaban relative to enoxaparin in the APEX trial.The median concentration of betrixaban among subjects administered the 80-mg dose was higher than that of the 40-mg dose (19 ng/mL vs 11 ng/mL, P.001). In the primary analysis cohort 1 (d-dimer ≥2× upper limit of normal), the primary efficacy outcome (asymptomatic proximal deep vein thrombosis, symptomatic proximal or distal deep vein thrombosis, symptomatic nonfatal pulmonary embolism, or venous thromboembolism-related death) was significantly reduced among subjects treated with 80 mg of extended-duration betrixaban versus enoxaparin (6.27% [95/1516] vs 8.39% [130/1549], relative risk reduction=0.26 [0.04-0.42], P=.023), and similarly in the entire primary efficacy outcome population (4.87% [122/2506] vs 7.06% [181/2562], relative risk reduction=0.30 [0.13-0.44], P=.001). There was no difference in the primary outcome for subjects treated with 40 mg betrixaban vs enoxaparin across cohorts. In addition, there was no excess of major bleeding associated with either betrixaban dose compared with enoxaparin.The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects.

Published
2016

37. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

Author

Engelbrecht, J., Finfer, S., Van Dyk, C., Cohen, Alexander, Grandes, J., Cepeda, J. M., NAZLIEL, BİJEN, Cohen, Alexander T., Efrati, S., Zakai, N., Yousef, K., Wichman, T., Whitman, B., Welker, J., Welch, M., Warner, A., Updegrove, J., Tuck, M., Stoltz, S., Sokol, S., Sharma, S., Shammas, N., Saba, F., Rodriguez, W., Rees, C., Rastogi, P., Rajan, R., Quintana, O., Pullman, J., Pratt, R., Pineda, L., Pearl, R., Parthiban, K., Overcash, J., Ortel, T., Ohaju, V., Nadar, V., Mittal, M., Milling, T., McLaren, G., Margolis, B., Mahal, S., Macchiavelli, A., Lopez, J., Lerner, R., Kung, M., Kouras, F., Kazimir, M., Kao, C-K., Kabler, H., Ioachimescu, O., Hazelrigg, M., Hamad, A., Haidar, A., Hahn, B., Goytia-Leos, D., Gaggin, H., Fulmer, J., Fraiz, J., Fermann, G., Farley, B., Doshi, A., Dhingra, R., Cornell, J., Concha, M., Clark, C., Chang, H., Carman, T., Bidair, M., Bercz, P., Bastani, A., Barney, J., Baker, S., Anderson, C., Amin, M., Almasri, E., Natarajan, I., McCollum, C., MacCallum, P., Davis, M., Body, R., Yagensky, A., Voronkov, L., Vishnivestsky, I., Vakaliuk, I., Ursol, G., Tseluyko, V., Svyshchenko, Y., Svyridova, I., Ryabichenko, T., Rudenko, L., Alekniene, B., Reshotko, D., Perepeliuk, M., Parkhomenko, O., Nikonov, V., Maslovaskyi, V., Malynovsky, Y., Legkonogov, O., Kyrychenko, I., Krakhmalova, O., Koshlia, V., Kopytsya, M., Karpenko, O., Gryb, V., Goncharova, Y., Goloborodko, B., Goloborodko, A., Godlevska, O., Burmak, I., Brozhyk, J., Batushkin, V., Abrahamovych, O., Tuncay, E., Topcuoglu, M., Tigen, K., Okumus, G., Kutluk, H., Kirma, C., Kilichesmez, K., Guneri, S., Akgul, O., Villalta, J., Vargas Nunez, J. A., Trujillo, J., Riera, A., Richart, C., Mellibovsky, L., Jimenez, D., Gonzales-Porras, J. R., Gomez Cerezo, J., Ferrer, R., Diaz Santos, E., Cereto, F., Castro Guardiola, A., Bisbe, J., Barbagelata Lopez, C., Alvarez Sala, L. A., Mitha, I., Breedt, J., Basson, M., Adler, D., Spisakova, M., Prokop, D., Payer, J., Krastev, G., Kokles, M., Hrubon, A., Herman, O., Dvorak, M., Cervenakova, A., Bodikova, S., Miloradovic, V., Kovacevic-Kuzmanovic, A., Ilic, S., Celic, V., Apostolovic, S., Vishnevskiy, A., Vishneva, E., Solovyov, O., Simanenkov, V., Shvarts, Y., Shpagina, L., Shapovalova, Y., Sergeeva, E., Reshetko, O., Privalova, E., Popov, D., Nilk, R., Nikolaev, K., Mordovin, V., Maslova, N., Martynenko, V., Martynenko, T., Malygin, A., Kostenko, V., Kosmacheva, E., Kobalava, Z., Klein, G., Khachatryan, N., Goloshchekin, B., Ershova, O., Dovgalevskiy, Y., Chefranova, Z., Boldueva, S., Bogdanov, E., Belskaya, G., Barbarash, O., Averkov, O., Arkhipov, M., Apartsin, K., Andreev, D., Abashev, A., Vida-Simiti, L., Stanciulescu, G., Stamate, S., Harrington, Robert A., Goldhaber, Samuel Z., Hull, Russell D., Popescu, M., Wiens, Brian L., Gold, Alex, Hernandez, Adrian F., Gibson, C. Michael, Harrington, Robert, Hull, Russell, Goldhaber, Samuel, Hernandez, Adrian, Ceresetto, Jose Manuel, Colquhoun, David, Pilger, Ernst, Polonetsky, Leonid, Podoleanu, C., Musetescu, R., Marin, I., Bojinca, M., Motte, Serge, Saraiva, Jose Francisco, Balogh, Z. E., Wrzesinski, K., Waldemar, K., Walasek, L., Raev, Dimitar, Mincheva, Valentina, Kahn, Susan, Sulik, P., Canon, Claudia Olivares, Malojcic, Branko, Mayer, Otto, Husted, Steen, Marandi, Toomas, Lassila, Riitta, Mottier, Dominique, Shaburishvili, Tamaz, Bauersachs, Rupert, Zeymer, Uwe, Hajko, Erik, Sobkowicz, B., Zeltser, David, Ageno, Walter, Krievins, Dainis, Bagdonas, Alfredas, Osores, Juan Lema, Tomkowski, Witold, Mot, Stefan, Panchenko, Elizaveta, Tan, Ru San, Gaspar, Ludovit, Jacobson, Barry, Monreal, Manuel, Ongen, Gul, Parkhomenko, Alexander, Uprichard, James, Pulkowski, G., Mirek-Bryniarska, E., Kucharski, L., Jastrzebski, D., Yusen, Roger, Grzelakowski, P., Merli, Geno, Gruenpeter, P., Gorecka, D., Gniot, J., Gaciong, Z., Fryze, W., Peacock, Frank, Schellong, Sebastian, Januzzi, James, Piovella, Franco, Cochet, Madeleine, Michalak, Nathan, Stepanchak, Maria, Spielman, Kathryn, Neal, Brandon, Florea, Ana, Chi, Gerald, Szlosek, Donald, Jain, Purva, Popma, Christopher, Korjian, Serge, Daaboul, Yazan, Halaby, Rim, Yanez, L. Toche, Lemor, Alejandro, Zacarkim, Marcelo, Romero, Gonzalo, Hernandez Elenes, Jesus Rosario, Alvarado, Alonso, Susheela, Ammu, Leitao, Meghan, Salas, M., Bandman, Olga, Horna, M., Strumph, Peter, Vinh, Nancy, Visona, A., Kostadinova, M., Vance, Annemarie, Moia, M., Wiens, Brian, Orlandini, F., Parisi, R., Pontaga, N., Smoak, Carey, Storgaard, M., Molteni, M., Castelino, Rennie, Goodman, Shelly, Stukena, I., Leeds, Janet, al-Khalidi, Hussein, Milanova, M., Karlo, L. Farjardo, Leimberger, Jeffrey, Phillips, Thomas, Rizos, T., Pencheva, G., Pomero, F., Francis, Charles, Novo, S., Pereyra, R. Cotrina, Tiefenbacher, C., Buller, Harry, Roberts, Robin, Prins, Martin, Weimar, C., Tuxen, C., Urhammer, S., Lember, M., Runev, N., Uuetoa, T., Spyropoulos, Alex, Carrier, Marc, Alkonyi, B., Lopes, Renato D., Horacek, T., Airaksinen, J., Honkaniemi, J., Pottier, P., Falukozy, J., Kaaja, R., Stoeva, N., Saarinen, J., Stoyanov, M., Pizzini, A., Devor, Adam, Tatlisumak, T., Kolls, Bradley, Dedrick, Joseph, Todd, Jamie, Jones, William Schuyler, Vikman, S., Agraou, B., Futo, L., Castillo Leon, R., Eapen, Zubin, Katona, A., Proust, A., Quere, I., Kirschner, R., Syulemzova, S., Valavicius, A., Todorov, G., Tokmakova, M., Dhar, A., Klimpe, S., Ahmad, Tariq, Brenna, J. Matthew, Douketis, J., Le Gal, G., Pearce, M., Susinskiene, D., Brito, Flavio, Provencher, S., Rozitis, V., Roy, P-M., Kroning, R., Gulack, Brian, Schmidt, J., Meza, James, Parikh, Kishan, Cooper, Lauren, Poskiene, R., Aquilanti, S., Lapp, H., Kristof, P., Lakatos, F., Laszlo, Z., Belhassane, A., Petrauskiene, R., Pagidipati, Neha, Simoneau, G., Verreault, S., Guimaraes, Patricia, Brisot, D., Perkins, Lynn M., De Geeter, G., Debourdeau, P., Alarcon, M. Arias, Lupkovics, G., Norviliene, R., Wilson, Matthew, Merkely, B., Lazcano, M. Opazo, Collier, Jeannie, Andras, C. Nagy, Cardenas, S. Potthoff, Butkovic-Soldo, S., Norvaisiene, R., Decoulx, E., Hayden, Nikieia, El Kouri, D., Car, S., Nemeth, L., Leizorovicz, Alain, Ciglenecki, N., Naudziunas, A., Datikashvili-David, I., Francetic, I., Jakopovic, M., Becker, Francois, Jennings, Lisa, Khabeishvili, G., Bello, F., Ferrari, A. E., Jure, H., Macin, S., Griskeviciene, V., Kalinic-Grgorinic, H., Falvo, N., Khintibidze, I., Grange, C., Kobulia, B., Knezevic, A., Megreladze, I., Marusic, S., Papp, A., Pagava, Z., Lawall, H., Oliva, M., Paposhvili, K., Parody, M., Amann, B., Soltesz, P., Sudar, Z., Butkiene, Z., Szabo, G., Vagic, J. Sikic, Szegedi, N., Poy, C., Timar, G., Skerk, V., Cermak, O., Valco, J., Baker, R., Coughlin, P., Vertes, A., Rubinfeld, A., Elias, M., Berrouschot, J., Gafter, A., Hayek, T., Chlumsky, J., Lacroix, P., Messas, E., Chochola, J., Cizek, V., Basijokiene, V., Hussein, O., Dunaj, M., Dusek, J., Huber, K., Lishner, M., Lugassy, G., Cerveri, I., D'Angelo, A., De Pellegrin, A., Francek, L., Havelka, J., Konig, J., Beyer-Westendorf, J., Herold, M., Holaj, R., Imberti, D., Landolfi, R., Blessing, E., Mathies, R., Schoenerr, H., Adzerikho, I., Koryk, V., Licka, M., Martinova, V., Horny, I., Mikhailova, E., Mitkovskaya, N., Pimanov, S., Polonetsy, L., Soroka, N., Blockmans, D., Delforge, M., Dive, A., Lienart, F., Bizzacchi, J. Annichino, Fiss, E., Mismetti, P., Freire, A., Hubac, J., Jajtner, P., Manenti, E., Ramacciotti, E., Lembo, G., Raymuno, S., Rocha, A., Kolman, P., Lang, P., Bott, M., Dengler, T., Mikulova, J., Dimov, B., Podpera, I., Reiterer, P., Dziewas, R., Montaclair, K., Genth-Zotz, S., Hamann, F., Paleiron, N., Spacek, R., Payot, L., Vejvoda, J., Vyhnanek, M., Christensen, H., Salvi, A., Lodigiani, C., Pernod, G., Grigorov, M., Lassen, M., Mumoli, N., Kalpachki, R., Kamenova, Z., Schenone, A., Guy's and St Thomas' Hospital [London], Stanford Medicine, Stanford University, Brigham and Women's Hospital [Boston], Thrombosis Research Unit, University of Calgary, Portola Pharmaceuticals (Portola), PORTOLA PHARMACEUTICALS, Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute (DCRI - DURHAM), Duke University [Durham], Beth Israel Deaconess Medical Center [Boston, USA], Harvard Medical School [Boston] (HMS), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), and Université de Brest (UBO)-Université de Brest (UBO)

Subjects
Male, Pyridines, Medizin, 030204 cardiovascular system & hematology, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Ultrasonography, Venous Thrombosis, Factors de risc en les malalties, Medicine (all), Acute Disease, Adult, Aged, Benzamides, Double-Blind Method, Drug Administration Schedule, Factor Xa Inhibitors, Female, Fibrin Fibrinogen Degradation Products, Hemorrhage, Hospitalization, Humans, Middle Aged, Pulmonary Embolism, Venous Thromboembolism, General Medicine, 3. Good health, Pulmonary embolism, Venous thrombosis, Cohort, medicine.medical_specialty, Patients, Risk factors in diseases, Placebo, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Thromboembolism, medicine, Pacients, Betrixaban, Thromboprophylaxis, Acutely Ill Medical Patients, Tromboembolisme, business.industry, Settore MED/09 - MEDICINA INTERNA, ta3121, Population cohort, medicine.disease, Surgery, chemistry, Once daily, business
Abstract

Background\ud Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.\ud \ud Methods\ud Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding.\ud \ud Results\ud A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55).\ud \ud Conclusions\ud Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.)

Published
2016

41. Does infant industry argument justify diversification policy in Argentinean wine sector?

Author

Khachatryan, N., Schuele, H., and Khachatryan, Armen

Subjects
spatial equilibrium analysis, infant industry argument, Agricultural and Food Policy, Food Consumption/Nutrition/Food Safety
Abstract

Since 1994 Argentinean government implemented the diversification policy to reduce wine supply in the domestic market and stabilize prices through reducing the share of grapes allocated for wine production in favour of must production. The policy has set a minimum percentage of grapes for concentrated grape must (CGM) production for every wine maker. The research aims to investigate the effects of the policy on the sector applying spatial equilibrium analysis, based on the model of Interregional Trade of Wine products in Argentina. The qualitative analysis of the sector under the current policy revealed, that the policy had a) no impact on the grape segment, b) a slight positive impact on grape must production due to 14% increased grapes reallocated from wine sector, and c) an expected but modest 20% decrease of wine production. The anticipated increase of wine and grapes prices was not observed. Moreover the policy affects largely the optimal recourse allocation process, because it encourages CGM production among others also in those regions, which have non favourable agro-climatic conditions for CGM production. The advantageous development of CGM segment benefiting from “infant industry argument” of the policy is although a positive outcome, on the long run it will cause stagnation and discourage investments for advanced technologies. The elimination of the diversification policy will ensure the competitive development of this emerging industry.

Published
2009

42. Should Russia comply with EU food safety norms in the wheat sector?

Author

Khachatryan, N., Schuele, H., Khachatryan, Armen, and Zeddies, Jurgen

Subjects
Agricultural and Food Policy, wheat, DRC, food safety standards, Food Consumption/Nutrition/Food Safety
Abstract

The impressive volumes of wheat production in Russia on the one hand, and the good baking quality of Russian wheat on the other hand enabled Russia to become one of the important wheat producers and exporters of the world since the recent few years. However Russia has a long way to go in the “front” of Sanitary and Phytosanitary (SPS), i.e. food safety, standards. As part of a larger study, financed by the German Research Foundation, the current research addresses the objective of estimating the potentials of wheat production in Russia under more stringent food safety standards as the current Russian national SPS regulations are. The comparative advantage analysis based on the Domestic Resource Cost approach (DRC) is applied to estimate the possible compliance of Russian norms with EU SPS standards. The DRC analysis resulting in a ratio of 0,37 provides evidence of high social profitability of wheat chain in Stavropol region. Also the scenarios of compliance of Russian food safety norms with those of EU offers plausible solutions with DRC ratios varying within the range of 0,49 – 0,96 dependent on the fluctuations of model parameters. This is the third paper from the series of analysis of competitiveness of the Russian wheat sector under different food safety policies. The first paper estimated the policy of the full enforcement of national SPS regulations . The second work assessed the policy of compliance with the international SPS norms and considered also the sensitivity analysis under this policy. As far as the EU SPS norms are more stringent as the international standards, there is a necessity to assess also this policy option.

Published
2009
Full Text
View/download PDF

44. Problems of Strategic Management Formation in Russian Agrarian Sector

Author

Bannikova, N., Schuele, H., Khachatryan, Armen, and Khachatryan, N.

Subjects
Farm Management
Abstract

The rapid changes in Russian agriculture during the last fifteen years require development of particular strategies for efficient farm management. The West-European approaches of strategic management and planning decisions are not directly applicable in the Russian agricultural economy; Russian large and medium-sized agricultural enterprises act on different organisational principles, due to the specific peculiarities of their business mentality. The objective of the research is to adopt modern strategic management concepts to the peculiarities of Russian agriculture and to work out proposals on formation of strategic planning system in agricultural production. To this end it is necessary to define the strategic planning features which take into account the nature of modern stage of the development of Russian economy and the specific character of agricultural production; to indicate the preconditions which promote the wide implementation of strategic planning into economic practice; to establish the features of the concept of strategic planning for agricultural enterprises and to elaborate a methodical set of instructions providing formalized character to strategic planning. Applying the methodologies of monographic research and expert interviews, we conducted the analysis of peculiarities and problems of Russian agricultural production, revealed and systematized the features of development of strategy for agricultural enterprises. Based on the results of our investigation we developed strategic development models for the agricultural enterprises of Stavropol region applying the approach of Strength /Neutral / Weakness (SNW) analysis of the methodology of comparative advantage. The usefulness and empirical value of the developed models have been approved on the example of “LUCH” agricultural enterprise, which is the first in the region according to effectiveness indicators and the fourth according to its relative size.

Published
2008

45. Modelling Interregional Trade of Energy Crops in Eastern Germany

Author

Khachatryan, N., Zeller, Heiko, Haring, Anna Maria, and Khachatryan, Armen

Subjects
International Relations/Trade, spatial equilibrium analysis, interregional trade, Energy crops
Abstract

Renewable resources gain in importance in our modern society. The line of reasoning is based on their positive effects on agriculture, the environment and the economy. To support renewable energy from biomass the EU promotes the cultivation of energy crops. A spatial equilibrium model is applied based on the concept of maximizing net welfare, to provide information whether energy crop production competes with food production for land area. The Model of Interregional Trade of Energy Crops (ITEC) refers to Eastern Germany and adjacent areas of Poland. First results show that the regions have enough feedstocks to meet the required demand for food and biofuel production. In many cases both food crops and biofuels are either traded on interregional basis or exported to "Rest of Europe" indicating that there is no competition between food and energy crops. Only green maize for biogas production strongly competes in areas where the crop is required as feed for cattle.

Published
2008
Full Text
View/download PDF

50. Optimisation of System Dynamics Models Using a Real-Coded Genetic Algorithm with Fuzzy Control

Author

Beklaryan Gayane L., Akopov Andranik S., and Khachatryan Nerses K.

Subjects
real-coded genetic algorithm, fuzzy control, system-dynamics, optimisation methods, Cybernetics, Q300-390
Abstract

This paper presents a new real-coded genetic algorithm with Fuzzy control for the Real-Coded Genetic Algorithm (F-RCGA) aggregated with System Dynamics models (SD-models). The main feature of the genetic algorithm presented herein is the application of fuzzy control to its parameters, such as the probability of a mutation, type of crossover operator, size of the parent population, etc. The control rules for the Real-Coded Genetic Algorithm (RCGA) were suggested based on the estimation of the values of the performance metrics, such as rate of convergence, processing time and remoteness from a potential extremum. Results of optimisation experiments demonstrate the greater time-efficiency of F-RCGA in comparison with other RCGAs, as well as the Monte-Carlo method. F-RCGA was validated by using well-known test instances and applied for the optimisation of characteristics of some system dynamics models.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results